No Data
No Data
Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children With the Introduction of Bébé Bottoms Diaper Rash Crème Spray
Made with TLC – Thin Layer Care Technology, New bébé Bottoms Diaper Rash Crème Spray Combines Zinc Oxide (10%) with Soothing Chamomile and Calendula in a Convenient, No-Touch Spray Application HAW
Chemical Linked to Cancer Found in Acne Creams Including Proactiv, Clearasil
Estée Lauder, Reckitt Fall Amid Cancer Risk in Acne Treatments
Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
Taro Pharmaceutical Industries Fiscal Q3 Net Income, Net Sales Rise; Shares Climb After Hours
Taro Pharmaceutical Industries (TARO) reported fiscal Q3 net income Thursday of $0.54, up from $0.19 a year earlier. A lone analyst polled by Capital IQ expected $0.30. Net sales in the quarter ended
Taro Pharmaceutical Indus Q3 Sales $157.10M Beat $154.91M Estimate
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly sales of $157.10 million which beat the analyst consensus estimate of $154.91 million by 1.42 percent. This is a 12.86 percent increase over s
No Data